Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

A Phase II Study to Assess the Safety and the Efficacy of Extracorporeal Photopheresis Using the Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

The present project is a prospective, multicenter, non-randomized, phase II trial which aims to evaluate the clinical impact and the safety of extracorporeal photopheresis (ECP) using the Theraflex system in patients with refractory chronic graft versus host disease (cGVHD) after any type of hematopoietic stem cell transplantation or after donor lymphocyte infusion.

Study Overview

• Status: Recruiting
• Conditions: Refractory Chronic Graft Versus Host Disease (cGVHD)
• Intervention / Treatment: Device: Photopheresis Theraflex ECP™

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Philippe Lewalle, MD, PhD; Phone Number: 32-2-5417208; Email: philippe.lewalle@bordet.be

Study Locations

• Belgium
  • Antwerpen, Belgium, 2060
    • Recruiting
    • Ziekenhuis Netwerk Antwerpen
    • Contact: Pierre Zachee, MD, PhD; Phone Number: 32-3-2177111; Email: pierre.zachee@zna.be
    • Principal Investigator: Pierre Zachée, MD, PhD
  • Brugge, Belgium, 8000
    • Recruiting
    • AZ Sint-Jan Brugge
    • Contact: Dominik Selleslag, MD; Phone Number: 32-50-453060; Email: dominik.selleslag@azbrugge.be
    • Contact: Tom Lodewyck, MD; Phone Number: 32-50-453060; Email: tom.lodewyck@azbrugge.be
    • Principal Investigator: Dominik Selleslag, MD
    • Sub-Investigator: Tom Lodewyck, MD
  • Brussels, Belgium, 1000
    • Recruiting
    • Institut Jules Bordet
    • Contact: Philippe Lewalle, MD, PhD; Phone Number: 32-2-5417208; Email: philippe.lewalle@bordet.be
    • Principal Investigator: Philippe Lewalle, MD, PhD
  • Edegem, Belgium, 2650
    • Recruiting
    • Universitair Ziekenhuis Antwerpen
    • Contact: Zwi Berneman, MD, PhD; Phone Number: 32-3-2204111; Email: zwi.berneman@uza.be
    • Principal Investigator: Zwi Berneman, MD, PhD
  • Gent, Belgium, 8000
    • Not yet recruiting
    • Universitair Ziekenhuis Gent
    • Principal Investigator: Tessa Kerre, MD, PhD
    • Contact: Lucien Noens, MD, PhD; Phone Number: 32-9-3323464; Email: Lucien.Noens@Ugent.be
    • Contact: Tessa Kerre, MD, PhD; Phone Number: 32-9-3323464; Email: Tessa.Kerre@Ugent.be
    • Sub-Investigator: Lucien Noens, MD, PhD
  • Jette, Belgium, 1090
    • Recruiting
    • Universitair Ziekenhuis Brussel
    • Contact: Rik Schots, MD, PhD; Phone Number: 32-2-4763105; Email: Rik.Schots@uzbrussel.be
    • Contact: Ann De Becker, MD; Phone Number: 32-2-4763105; Email: Ann.Debecker@uzbrussel.be
    • Principal Investigator: Rik Schots, MD, PhD
    • Sub-Investigator: Ann De Becker, MD
  • Liège, Belgium, 4000
    • Recruiting
    • CHU Liege
    • Contact: Yves Beguin, MD, PhD; Phone Number: 32-4-3667201; Email: yves.beguin@chu.ulg.ac.be
    • Contact: Frédéric Baron, MD, PhD; Phone Number: 32-4-3667201; Email: F.Baron@ulg.ac.be
    • Principal Investigator: Yves Beguin, MD, PhD
    • Sub-Investigator: Frederic Baron, MD, PhD
    • Sub-Investigator: Evelyne Willems, MD
  • Woluwe-Saint-Lambert, Belgium, 1200
    • Recruiting
    • Cliniques Universitaires Saint-Luc
    • Contact: Xavier Poiré, MD; Phone Number: 32-2-7641809; Email: Xavier.Poire@uclouvain.be
    • Principal Investigator: Xavier Poiré, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have chronic GVHD (cGVHD) occurring after any type of HSC transplantation : with any type of donor (HLA-identical siblings or HLA-matched or mismatched family or unrelated donor); with any type of conditioning (full-intensity, reduced-intensity, nonmyeloablative, no conditioning); with any type of HSC (bone marrow, PBSC, cord blood) or after donor lymphocyte infusion.
• Patients must have cGVHD primarily affecting at least one of the following organs: skin; oral mucosal; eye; liver; lung; joints; fascia. Gastro-intetinal (GI) cGVHD alone is not a sufficient inclusion criterion.
• Patients must have cGVHD that has already been treated with first-line systemic therapy for at least 1 month at effective doses. First-line systemic therapy must have included at least prednisolone 1 mg/kg/day or equivalent. In case of formal contraindication to steroid therapy, first-line systemic therapy must have included therapeutic doses of at least one of the following drugs: tacrolimus or ciclosporine (if patient not treated with a calcineurin inhibitor at onset of cGVHD), sirolimus, everolimus, mycophenolate mofetyl.
• Patients must require further salvage therapy for cGVHD because of either refractoriness or contraindication/intolerance to current therapy.

Need for salvage therapy is defined by any of the following criteria :

• the development of 1 or more new sites of disease while being treated for chronic GVHD
• progression of existing sites of disease while receiving treatment for chronic GVHD
• failure to improve despite at least 1 month of standard treatment for chronic GVHD,

• relapse/progression of cGVHD while tapering current treatment for cGVHD.

  • Patients may have received any number of previous lines of treatment for cGVHD.
  • Concomitant treatment with other immunosuppressors is allowed if they were started and maintained at constant dosage for at least one month before the start of ECP. Shorter delay can be accepted for patients with highly progressive GVHD requiring salvage therapy.
  • Signed informed consent.
  • Any age.
  • Weight > 15 Kg (because of leukapheresis). Weight <15 Kg is acceptable if a suitable method of leukapheresis has been developed and approved at site.

Exclusion Criteria:

• Patient has received any investigational agent for chronic GVHD in the past 4 weeks.
• Patient has started a new line of systemic therapy for cGVHD in the past 4 weeks. Shorter delay can be accepted for patients with highly progressive GVHD requiring salvage therapy.
• Known sensitivity to psoralen compounds such as 8-methoxypsoralen
• Comorbidities that may result in photosensitivity (coexisting skin cancer or photosensitive disease (such as porphyria, lupus, albinism…)
• Aphakia. MOP is contraindicated in patients with aphakia, because of the significantly increased risk of retinal damage due to the absence of lenses
• Known allergy to one of the components used in apheresis (e.g., heparin and citrate).
• History of heparin-induced thrombocytopenia or patients with serious coagulation disorders.
• Unable to tolerate the apheresis procedure including extracorporeal volume shifts because of uncompensated congestive heart failure, pulmonary edema, severe lung disease, severe renal failure, hepatic encephalopathy, or any other reason.
• Bilirubin > 25 mg/L.
• Absolute neutrophil count < 1.0 x 109 / L despite use of growth factors
• Platelet count < 20 x 109 / L despite platelet transfusion
• HIV seropositivity.
• Uncontrolled infection
• Relapse or progression of the hematological malignancy.
• Eastern Cooperative Oncology Group (ECOG) score > 2.
• Pregnancy or breastfeeding
• Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment.
• Any serious illness with expected survival less than 6 months.
• Any clinically significant medical or other condition that in the investigator's opinion could interfere with the administration of photopheresis or interpretation of study results, or compromise the safety or wellbeing of the patient.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Photopheresis Theraflex ECP™; All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.	Device: Photopheresis Theraflex ECP™; The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response rates of chronic GVHD to the Theraflex ECP treatment.	Percentage of patients reaching complete response, percentage of patients reaching partial response.	During the study (8 years and 2months)
Duration of response.	Time from achieving at least a partial response to the time of progression.	During the study (8 years and 2months)
GVHD-partial response survival.	Time from partial response to either the first progression of GVHD or the date of death, whichever occurs first.	During the study (8 years and 2months)
GVHD-free Interval.	Interval from the date of complete response to the date of the first progression of GVHD.	During the study (8 years and 2months)
GVHD-free survival.	Time fromcomplete response to either the first progression of GVHD or the date of death, whichever occurs first.	During the study (8 years and 2months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of steroid dose saving.	Percentage of dose reduction from the date of first ECP to the lowest dose of steroids taken by the patient during a minimum of 3 months (except in case of dose reduction due to adverse events related to steroids)	During the study (8 years and 2months)
Discontinuation of immunosuppressive drugs during the ECP treatment		During the study (8 years and 2months)
Occurrence of adverse events and serious adverse events related to extracorporeal photopheresis.		During the study (1 year of follow up after the last treatment)
Incidence of viral, bacterial, fungal and parasitic infections		During the study (8 years and 2months)

Collaborators and Investigators

• Sponsor: Jules Bordet Institute
• Collaborators: Macopharma; Belgian Hematological Society
• Investigators: Principal Investigator: Philippe Lewalle, MD, PhD, Jules Bordet Institute

Study record dates

Study Major Dates

• Study Start: September 1, 2014
• Primary Completion (Anticipated): September 1, 2022
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: January 14, 2015
• First Submitted That Met QC Criteria: March 13, 2017
• First Posted (Actual): March 20, 2017

Study Record Updates

• Last Update Posted (Actual): March 20, 2017
• Last Update Submitted That Met QC Criteria: March 13, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Keywords: Hematology; Hematopoietic stem cell transplantation; Extracorporeal photopheresis; Chronic graft versus host disease (cGVHD); Donor lymphocyte infusion
• Additional Relevant MeSH Terms: Immune System Diseases; Graft vs Host Disease
• Other Study ID Numbers: BHS-TC-11